Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Testicular germ cell expressed HSF2 interacting long non-coding RNA (TESHL), more commonly referred to as DIRC3-AS1 or LINC01921, is a nuclear long non-coding RNA (lncRNA) involved in the *cis*-regulation of neighboring tumor suppressor genes, particularly IGFBP5[1][2][3]. DIRC3 (a synonym) is regulated by melanoma-associated transcription factors MITF and SOX10, and functions by modulating local chromatin structure and repressing SOX10 binding, thereby activating IGFBP5 expression and exerting tumor suppressive effects[2][3]. Low levels of expression in melanoma are associated with decreased patient survival, suggesting its potential as a biomarker in this context[3]. There is no evidence that TESHL functions as a traditional druggable target (such as a receptor, enzyme, or transporter) or has known small molecule or biologic drug modulators, nor is it typically classified as a therapeutic target[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Testicular germ cell expressed HSF2 interacting long non-coding RNA (TESHL).